CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping Into a Booming $20 Billion Market
CBD Life Sciences (CBDL) launches a new line of mushroom-infused gummies targeting the wellness market, projected to reach $20 billion by 2030 with a 14% annual growth rate. The product line includes three formulations: Rise Gummies for focus and energy (containing Lion's Mane Mushroom, B12, and Ginseng), Dream Gummies for sleep and relaxation (with Reishi Mushroom, Kava, and 5-HTP), and Bloom Gummies for sexual wellness (featuring Cordyceps Mushroom and other natural ingredients). This strategic launch aims to capitalize on growing consumer demand for natural wellness products and create new revenue streams.
CBD Life Sciences (CBDL) lancia una nuova linea di caramelle gommose infuse con funghi, rivolta al mercato del benessere, che si prevede raggiungerà 20 miliardi di dollari entro il 2030 con un tasso di crescita annuo del 14%. La linea di prodotti include tre formulazioni: Rise Gummies per concentrazione ed energia (contenenti Funghi Lion's Mane, B12 e Ginseng), Dream Gummies per sonno e rilassamento (con Funghi Reishi, Kava e 5-HTP) e Bloom Gummies per il benessere sessuale (caratterizzate da Funghi Cordyceps e altri ingredienti naturali). Questo lancio strategico mira a capitalizzare la crescente domanda dei consumatori per prodotti di benessere naturali e a creare nuovi flussi di entrate.
CBD Life Sciences (CBDL) lanza una nueva línea de gomitas infusionadas con hongos que se dirigen al mercado del bienestar, que se proyecta alcanzará 20 mil millones de dólares para 2030 con una tasa de crecimiento anual del 14%. La línea de productos incluye tres formulaciones: Rise Gummies para enfoque y energía (que contienen hongo Lion's Mane, B12 y ginseng), Dream Gummies para dormir y relajación (con hongo Reishi, Kava y 5-HTP), y Bloom Gummies para el bienestar sexual (con hongo Cordyceps y otros ingredientes naturales). Este lanzamiento estratégico tiene como objetivo capitalizar la creciente demanda de los consumidores por productos de bienestar naturales y crear nuevas fuentes de ingresos.
CBD Life Sciences (CBDL)가 웰니스 시장을 겨냥한 버섯이 주입된 새로운 젤리 라인을 출시했습니다. 이 시장은 2030년까지 200억 달러에 이를 것으로 예상되며 연간 14% 성장률을 기록할 것으로 보입니다. 제품 라인에는 Rise Gummies (Lion's Mane 버섯, B12 및 인삼 포함)로 집중력과 에너지를 위한 제품, Dream Gummies (Reishi 버섯, 카바 및 5-HTP 포함)로 수면 및 이완을 위한 제품, Bloom Gummies (Cordyceps 버섯 및 기타 천연 성분 포함)로 성 건강을 위한 제품이 포함됩니다. 이 전략적 출시는 자연 웰니스 제품에 대한 소비자 수요 증가에 따라 수익원을 창출하려는 목표를 가지고 있습니다.
CBD Life Sciences (CBDL) lance une nouvelle gamme de bonbons gélifiés infusés aux champignons visant le marché du bien-être, qui devrait atteindre 20 milliards de dollars d'ici 2030 avec un taux de croissance annuel de 14%. La ligne de produits comprend trois formulations : Rise Gummies pour la concentration et l'énergie (contenant du champignon Lion's Mane, de la B12 et du ginseng), Dream Gummies pour le sommeil et la relaxation (avec du champignon Reishi, du Kava et du 5-HTP), et Bloom Gummies pour le bien-être sexuel (présentant des champignons Cordyceps et d'autres ingrédients naturels). Ce lancement stratégique vise à capitaliser sur la demande croissante des consommateurs pour des produits de bien-être naturels et à créer de nouvelles sources de revenus.
CBD Life Sciences (CBDL) bringt eine neue Linie von mit Pilzen angereicherten Gummibärchen auf den Markt, die sich an den Wellness-Sektor richtet. Es wird erwartet, dass dieser Markt bis 2030 20 Milliarden Dollar erreichen wird und eine jährliche Wachstumsrate von 14% aufweist. Die Produktlinie umfasst drei Formulierungen: Rise Gummies für Konzentration und Energie (mit Lion's Mane-Pilz, B12 und Ginseng), Dream Gummies für Schlaf und Entspannung (mit Reishi-Pilz, Kava und 5-HTP) sowie Bloom Gummies für sexuelle Gesundheit (mit Cordyceps-Pilz und anderen natürlichen Inhaltsstoffen). Dieser strategische Launch zielt darauf ab, die wachsende Verbraucher Nachfrage nach natürlichen Wellness-Produkten zu nutzen und neue Einnahmequellen zu schaffen.
- Entry into rapidly growing mushroom market with 14% annual growth rate
- Diversification of product portfolio with three distinct wellness formulations
- Targeting high-demand wellness categories (energy, sleep, sexual health)
- None.
Projected to reach the
SCOTTSDALE, AZ / ACCESSWIRE / October 31, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL) sets a new industry standard with its launch of a high-performance line of mushroom-infused gummies, designed to meet the surging demand for wellness products in a projected
With an expanding consumer focus on holistic health and functional ingredients, CBDL's Rise, Dream, and Bloom Gummies each bring targeted benefits, including cognitive enhancement, restful sleep, and boosted vitality. These products are strategically positioned to address top wellness priorities, blending potent natural ingredients with advanced formulation technology. This launch is expected to significantly contribute to CBDL's revenue stream, enhancing shareholder value and setting the company apart as an innovator in functional wellness.
Targeted Wellness Meets Market Demand: Three Powerful Formulations
Rise Gummies are formulated to support focus and energy, each containing 500mg of Lion's Mane Mushroom, 1 microgram of B12, and 25mg of Ginseng. This combination aligns with a growing segment of consumers seeking natural solutions to boost mental clarity and productivity.
Dream Gummies provide natural support for relaxation and sleep, with 500mg of Reishi Mushroom, 25mg of Kava, and 10mg of 5-HTP. With sleep wellness now a top priority for many, Dream Gummies offer a non-habit-forming solution to support stress relief and emotional balance.
Bloom Gummies offer a targeted formula for sexual wellness and vitality, incorporating 500mg of Cordyceps Mushroom along with Tongkat Ali, Ginkgo Biloba, Ginseng, L-Arginine, Ashwagandha, and Maca. This powerful combination is designed to support libido, energy, and overall wellness, meeting the needs of consumers prioritizing vitality and balance.
A Game-Changing Opportunity for Growth and Profitability
The global mushroom market, projected to reach
Furthermore, as CBDL advances in this sector, its market differentiation promises significant potential for profit, brand expansion, and sustained shareholder value. With early adoption into these emerging wellness sectors, CBDL is creating a scalable pathway for growth, ensuring long-term profitability and new revenue channels, particularly attractive to investors.
Why Investors Should Take Note
This new product line underscores CBDL's commitment to innovation and market leadership, poised to drive substantial revenue growth. With the functional gummy market projected to grow at over
For existing and potential investors, CBDL's mushroom gummy line represents an unmatched opportunity for portfolio growth. The anticipated success of Rise, Dream, and Bloom Gummies is expected to boost CBDL's market share and generate heightened interest from strategic retail partners, translating into higher returns and increased shareholder equity. With its pioneering approach to wellness, CBDL is dedicated to securing sustained value for investors by remaining at the forefront of natural health innovation.
About CBD Life Sciences, Inc.
CBD Life Sciences, Inc. (OTC PINK:CBDL) is a leading innovator in the CBD and wellness industry, committed to creating high-quality, scientifically backed products that promote health and well-being. From pain relief to overall wellness, CBD Life Sciences strives to deliver top-tier solutions that meet the needs of today's consumers.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
Related Images
|
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
FAQ
What new products did CBD Life Sciences (CBDL) launch in October 2024?
What is the projected market size for CBDL's mushroom products by 2030?
What ingredients are in CBDL's Rise Gummies?
